May 16, 2024
Eli Lilly has announced positive phase 3 topline results for its once-weekly insulin efsitora alfa (efsitora) in insulin-naive adults with type 2 diabetes and those who […]
May 15, 2024
TOPLINE: Individuals with overweight and obesity who reach a weight loss plateau at around 6 months on a healthy weight loss diet may not achieve further […]
May 15, 2024
DENVER — In addition to the established gastrointestinal side effects common with the highly effective anti-obesity drugs, there is growing discussion around their potential to contribute […]
May 15, 2024
TOPLINE: Setmelanotide treatment over a 16-week period leads to a consistent decrease in both bodyweight and hunger among patients with hypothalamic obesity, according to the results […]
May 15, 2024
COPENHAGEN (Reuters) – Novo Nordisk does not expect a shortage of its Wegovy weight-loss drug in Denmark despite an earlier warning by the Danish Medicines Agency […]
May 14, 2024
(Reuters) – Eli Lilly has entered into a settlement deal with a medi spa that had sold counterfeit versions of its popular diabetes drug Mounjaro and […]
May 14, 2024
VENICE, Italy — Four-year data from the SELECT cardiovascular outcomes trial show that the anti-obesity drug semaglutide (Wegovy) leads to clinically significant and durable weight loss […]
May 14, 2024
VENICE, ITALY — Personalized doses and slow tapering of semaglutide (Wegovy or Ozempic, Novo Nordisk) in patients who also follow a digital weight loss program can […]
May 14, 2024
NEW ORLEANS — Adrenalectomy for the treatment of mild autonomous cortisol secretion (MACS) appears to improve bone quality but not bone density, new data suggested. Formerly […]